Pangaea OncologyXMAD:PANG 63 Gross Margin % is 97.83% as of Dec. 2025, which is 13% below its 10-year median of 112.43. GuruFocus rates XMAD:PANG with a GF Score™ of 63/100 and a GF Value™ of €2.15 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Pangaea Oncology ranks better than 97.94% on this metric.
Pangaea Oncology SA gross margin has been in long-term decline. The average rate of decline per year is -2.5%.
The historical rank and industry rank for Pangaea Oncology's Gross Margin % or its related term are showing as below:
XMAD:PANG'
s Gross Margin % Range Over the Past 10 Years
Min: 94.14 Med: 112.43 Max: 140.29
Current: 99.28
During the past 13 years, the highestGross Margin % of Pangaea Oncology was 140.29%. The lowest was 94.14%. And the median was 112.43%.
XMAD:PANG's Gross Margin % is ranked better than 97.94% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 51.14
vs XMAD:PANG: 99.28
Pangaea Oncology had a gross margin of 97.83% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Pangaea Oncology was -2.50% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Pangaea Oncology had a gross margin of 97.83% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Pangaea Oncology Gross Margin % Related Terms
Pangaea Oncology Gross Margin % Historical Data
* Premium members only.
The historical data trend for Pangaea Oncology's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:PANG vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Pangaea Oncology's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pangaea Oncology Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Pangaea Oncology's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Pangaea Oncology (XMAD:PANG) has a Gross Margin % of 97.83% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Pangaea Oncology and its competitors. This is 13% below median its historical median of 112.43. Over the past decade, Pangaea Oncology's Gross Margin % has ranged from 94.14 to 140.29. According to the industry distribution chart, Pangaea Oncology ranks #4 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 2.1%.
Is Pangaea Oncology's Gross Margin % too high?
Pangaea Oncology's current Gross Margin % of 97.83% is 13% below median its 10-year median of 112.43. Over the past 10 years, this metric has ranged from a low of 94.14 to a high of 140.29. The Medical Diagnostics & Research industry median Gross Margin % is 51.14. Pangaea Oncology's value of 97.83% is 91.3% above this industry median. Based on the distribution chart, Pangaea Oncology ranks #4 out of 194 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Pangaea Oncology has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pangaea Oncology ranks #4 out of 194 companies for Gross Margin %. This places Pangaea Oncology in the top 2% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 51.14. Pangaea Oncology's value of 97.83% is 91.3% above this benchmark. Historically, Pangaea Oncology's own Gross Margin % has ranged from 94.14 to 140.29 over the past decade. While the company's 10-year median is 112.43 vs. the industry median of 51.14, Pangaea Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 51.14, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pangaea Oncology's current Gross Margin % of 97.83% is 91.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Pangaea Oncology and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 51.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pangaea Oncology's current Gross Margin % is 97.83%, which is 13% below median its own 10-year median of 112.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Possible Value Trap. The stock's GF Value™ is €2.15, compared to a current price of €1.51 — trading 29.8% below its estimated fair value. The current Gross Margin % is 97.83%, which is 13% below median its 10-year median of 112.43 and 91.3% above the Medical Diagnostics & Research industry median of 51.14. Pangaea Oncology's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current Gross Margin % is 97.83% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?
Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued.
The current stock price of €1.51 is trading 29.8% below its estimated GF Value™ of €2.15.
GuruFocus considers Pangaea Oncology to be Possible Value Trap.
Key valuation signals for XMAD:PANG:
Gross Margin %: 97.83% (13% below median its 10-year median of 112.43)
GF Value™: €2.15 vs. price of €1.51 (29.8% below fair value)
Industry Position: 91.3% above the Medical Diagnostics & Research median (#4 of 194)
No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
63GF Score
Get the complete analysis for XMAD:PANG
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PANG has been successfully added to your 
